Ascentage Pharma Group International has announced the release of results from multiple clinical studies at the 2025 European Hematology Association (EHA) Hybrid Congress. The company presented findings from 13 studies focusing on its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918. Notably, olverembatinib demonstrated significant therapeutic potential and clinical benefits in treating Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia $(ALL)$, with high complete remission and molecular response rates. Additionally, a preclinical study on APG-5918 showed its potent antitumor activity in T-cell lymphoma, supporting further clinical development. The results were featured in various formats, including poster presentations at the congress.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。